AIM Vaccine Co., Ltd.
艾美疫苗股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 06660)

VOLUNTARY ANNOUNCEMENT APPLICATION FOR CLINICAL TRIAL OF THE MRNA SHINGLES/HERPES ZOSTER VACCINES T-CELL IMMUNITY, IgG ANTIBODY TITERS AND FLUORESCENT ANTIBODY TO MEMBRANE ANTIGEN TITERS WERE SIGNIFICANTLY HIGHER THAN THOSE OF COMMERCIALLY AVAILABLE RECOMBINANT SUBUNIT VACCINES

This announcement is made by AIM Vaccine Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business developments of the Group.

Following the established corporate strategy, the Group proactively advances the development of the vaccine product pipelines, and leverages the advantages of the mRNA technology platform to accelerate the research and development of mRNA vaccine series products through on-going technological innovation. The application for clinical trial of the mRNA shingles/herpes zoster vaccines developed by the Group has been submitted to the Center for Drug Evaluation (CDE) of National Medical Products Administration of China recently.

In preclinical animal testing, results from a third-party testing unit showed that the Group's mRNA shingles/herpes zoster vaccine specific T-cell immunity, specific IgG antibody titers, and fluorescent antibody to membrane antigen (FAMA) titers were significantly higher than those of commercially available recombinant subunit control vaccines.

Shingles/herpes zoster virus is unique in that it remains latent for life after the initial infection and T-cells mediate absolute immune protection. It reduces the risk of developing shingles/herpes zoster by increasing specific T-cell immunity to prevent the virus from reactivating and controlling intracellular infection. This corresponds to the advantages of the mRNA vaccine, which is effective in inducing T-cell responses without the addition of adjuvants and has no safety risks associated with adjuvants. Currently, no mRNA shingles/herpes zoster vaccine has been approved for marketing in the world. The vaccination rate of shingles/herpes zoster vaccine in the target population is only about 0.1%, leaving much room for improvement. In 2023, the global sales of GSK shingles/herpes zoster vaccine reached approximately US$4.286 billion. According to the forecast of China Insights Industry Consultancy Limited, an industry consultant, it is expected that the market size of shingles/herpes zoster vaccines in China will reach approximately RMB20.0 billion and the global market size will reach approximately US$23.9 billion by 2030. Upon approval of the product for marketing, it will bring considerable growth to the Group's performance.

The Group has established a sound quality management system for mRNA vaccines and a commercial-scale production workshop in line with GMP standards, and the mRNA technology platform have been verified by tens of thousands of human clinical trials data of mRNA vaccine products. The Group has now smoothened the whole life cycle process such as the research, development and production of mRNA vaccines, allowing for rapid achievement of the industrialization and commercialization of mRNA vaccine products after obtaining clinical approval.

By order of the Board
AIM Vaccine Co., Ltd.
Mr. Yan ZHOU
Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, February 11, 2025

As at the date of this announcement, the Board of the Company comprises Mr. Yan ZHOU, Mr. Xin ZHOU, Mr. Wen GUAN, Mr. Shaojun JIA and Mr. Jie ZHOU as executive directors; Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive directors; and Professor Ker Wei PEI, Mr. Hui OUYANG, Ms. Jie WEN and Mr. Xiaoguang GUO as independent non-executive directors.